title: [Establishment of a cisplatin-multidrug resistance cell line of human osteosarcoma].
abstract: OBJECTIVE
  To establish a multidrug resistance cell line of human osteosarcoma from the MG63 cell line and to test its attributes.
  
  
  METHODS
  The human osteosarcoma MG63 cells were exposed to high and gradually increased dose of cisplatin for 186 days to introduce its multidrug resistance (MG63/R). The sensitivity of the multidrug resistance was measured by MTT assay. The morphology and ultramicrostructure of the cells were observed using optical microscopy and transmission electron microscopy. The proliferation ability of the cells was measured by growth curve and colony-forming assay. The cell cycle and apoptosis and the expression of P-pg, bcl-2, P53 in the MG63 and MG63/R cell lines were analyzed by flow cytometry.
  
  
  RESULTS
  The resistance index of the MG63/R cells to cisplatin was 83.557 +/- 4.841. The cells also had resistance to doxorubicin, vincristin, methotrexate and cyclophosphamide. Disordered structure of the MG63/R cells was observed through microscopy. The cells appeared in triangle, polygon and polynucleation. The increase of granular endoplasmic reticulums and apophyses was observed through transmission electron microscopy. The proliferation ability of MG63/R increased significantly, with a low apoptosis index. Compared to the MG63, the expressions of P-pg and bcl-2 in the MG63/ R increased while the expression of P53 decreased.
  
  
  CONCLUSIONS
  A multidrug resistance cell line (MG63/R) of human osteosarcoma is established, which will benefit to further studies as a new experimental model.
authors.affiliation: Department of Orthopaedics, West China Hospital, Sichuan University, Chengdu 610041, China.
authors.forename: Wen-Tao
authors.initials: WT
authors.lastname: Zhang
authors.forename: Chong-Qi
authors.initials: CQ
authors.lastname: Tu
authors.forename: Yang
authors.initials: Y
authors.lastname: Liu
authors.forename: Sheng-Fu
authors.initials: SF
authors.lastname: Li
mesh_terms: D001859:Bone Neoplasms / Q000473:pathology*; D045744:Cell Line, Tumor; D002945:Cisplatin / Q000494:pharmacology*; D004317:Doxorubicin / Q000494:pharmacology; D018432:Drug Resistance, Multiple; D019008:Drug Resistance, Neoplasm; D006801:Humans; D012516:Osteosarcoma / Q000473:pathology*; D014750:Vincristine / Q000494:pharmacology
chemical_list: D014750:Vincristine; D004317:Doxorubicin; D002945:Cisplatin